Susquehanna International Group, LLP Bio Line Rx Ltd. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 87,215 shares of BLRX stock, worth $305,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,215
Previous 18,032
383.67%
Holding current value
$305,252
Previous $9,000
111.11%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BLRX
# of Institutions
36Shares Held
2.83MCall Options Held
75.1KPut Options Held
5.1K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.54 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.85 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$582,5710.02% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$329,4650.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92KShares$322,0000.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $215M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...